Cornell Bio's core products released the latest data, followed by a sharp drop of nearly 40% in stock price
万小盈
发表于 2023-11-22 19:02:30
1329
0
0
On November 21st, Cornell Bio announced IL-4R α 52 week clinical data on the treatment of moderate to severe atopic dermatitis with monoclonal antibody drug Rademikabart.
According to the official website of Cornell Biology, this is the second phase of the Chinese trial for the development of this new drug, which means that Rademikabart continues the patient improvement observed in the 16th week of the first phase; Moreover, patient improvement occurs in both biweekly and weekly dosing regimens. Among them, the frequency of administration every four weeks is lower than that of currently approved therapies, which reflects the potential of the drug.
On the same day, with the release of key clinical progress information, Kangnaide Biotechnology also granted Rademikabart's Greater China rights exclusively to Xiansheng Pharmaceutical. The advance payment for this cooperation is approximately 150 million yuan, with milestone payments up to 875 million yuan.
Moreover, according to the agreement, Xiansheng Pharmaceutical will not only be responsible for Rademikabart's new drug application for atopic dermatitis indications in China, but also for Rademikabart's future clinical research and expenses for all other disease indications in the Greater China region. This also means that Cornell Bio has transferred most of the rights of Rademikabart located in Greater China to Xiansheng Pharmaceutical, while retaining the right to develop and commercialize this product in other markets.
On the secondary market, the stock price of Conrad Biotech fell by over 38% on November 21, with a closing price of $1.26/share and the latest market value of $69.39 million. During the period from July to October this year, the stock price of Conrad Biotech has dropped below $1 per share, almost on the brink of delisting.
Conrad Biotech was listed on NASDAQ in March 2021. This company was founded by Pan Wubin and his scientist friend Zheng Wei in Taicang, Jiangsu in 2012. The main challenge for enterprises in the field of diseases is focused on autoimmune diseases and inflammation treatment.
Rademikabart, also known as the once highly anticipated CBP-201 project. This drug targets IL-4R α (IL-4R α A whole human monoclonal antibody that is a common subunit of IL-4 receptors and IL-13 receptors. From the perspective of drug principles, Rademikabart and IL-4R α After combination, attempts can be made to block the functions of IL-4 and IL-13, thereby blocking the Th2 type inflammatory pathway and achieving the goal of treating a series of Th2 related inflammatory diseases such as atopic dermatitis and asthma. Therefore, in addition to atopic dermatitis, another focus of this drug is the treatment of asthma.
The reason why it was once highly anticipated is that there is currently only one approved IL-4R globally α Targeted drug, also known as Duprizumab, jointly developed by Sanofi and Regenerated Element. In history, on March 28, 2017, Duprizumab received the first approval from the US Food and Drug Administration for the treatment of adult patients with moderate to severe atopic dermatitis. According to Sanofi's semi annual report, global sales of Duprizumab in the first half of this year reached 4.878 billion euros, approximately 5.366 billion US dollars.
It is worth noting that on November 17th, Sanofi announced that Duprizumab was approved in China for maintenance treatment in adolescents and adults aged 12 and above with asthma. This also means that as of now, the approved indications for Duprizumab in China have covered both atopic dermatitis and asthma, and the indications for atopic dermatitis also enjoy medical insurance payments. This clearly increases the competitive pressure on Cornell Bio and Xiansheng Pharmaceutical in the domestic market.
At the beginning of its birth, Rademikabart was considered a heavyweight product that could potentially impact billions of dollars in products against the standard Prizumab. This also helped Conrad Bio attract a large amount of financing, including Qiming Venture Capital, which was once known as the "Taicang Unicorn". However, there has always been no evidence of superior efficacy from the biological aspect of Conrad.
On January 5, 2022, Cornell Bio disclosed detailed data from the Rademikabart experiment. The company believes that Rademikabart's 300mg treatment regimen is competitive. However, on January 5th and 6th of that year, the stock price of Conrad Bio plummeted for two consecutive days.
In addition, in addition to Rademikabart, a "star drug" that has now been handed over to Xiansheng Pharmaceutical, on May 3, 2022, Conrad Biotech announced that in another heavyweight product, the CBP-307 project, the main endpoint showed numerical improvement, but did not reach statistical significance. The company is preparing to authorize CBP-307 externally. This action is interpreted by the market as' selling children for survival '. Subsequently, on May 4th, the company's stock price fell by over 57%, closing at $0.82 per share, falling below $1.
According to the official website of Cornell Bio, in the company's current product pipeline, apart from the two focus products CBP-201 and CBP-307, only CBP-174 (small molecule, target not disclosed), CBP-233 (IL-33 monoclonal antibody), CBP-246 (antibody targeting IL-1RAcP), and CBP-403 (bispecific mAb targeting Th2 cytokines) have entered the clinical stage.
According to financial information, as of June 30 of this year, the cash, cash equivalents, and short-term investments of Kangnaide Biotechnology amounted to RMB 950.7 million, which was RMB 1127.3 million at the end of 2022. The company stated that the main reason for the decrease in this data is continuous research and development. Cornell Bio believes that according to its operating plan, it has sufficient cash and investment to support it until 2026.
In addition, as of the end of June this year, the administrative expenses of Cornell Bio have been reduced to RMB 56.2 million. During the same period, this data was 71.8 million RMB. As of the first half of this year, the company had a total net loss of RMB 212 million.
Currently, Cornell Bio also has Rademikabart conducting a global phase II trial on asthma indications. In the press release of China Daily, the company stated that it is expected to complete the trial, and the final visit of the last patient is expected to take place in October of this year. In June of this year, Conrad Biotech also released positive data on the maintenance period of the second phase clinical trial of CBP-307 in the treatment of moderate to severe ulcerative colitis until 48 weeks.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- Starbucks CEO changes, daily stock price rises record breaking
- Three CEOs replaced within two years, Starbucks moves in as' Fire Captain ', stock price skyrockets
- Est é e Lauder's stock price gave up earlier gains and fell 7.3% at one point
- Baidu: Q2 core profit growth of 23% exceeds expectations, cloud business accelerates growth
- After being shorted by Hindenburg, the performance report was postponed and the stock price of Supermicro Computer plummeted by 26%
- Q2 performance growth is strong, and the stock price of Yaduo Group has risen by 13.32%
- Over 40% of hotel bookings cannot be cancelled after being booked, and six major platforms including Ctrip and Tuniu have been interviewed
- 호텔 10명 중 4명은 예약 후 씨트립, 투우 등 6대 플랫폼을 취소할 수 없다
- ASME's stock price fell by 6%, and other chip stocks followed suit and fell
- Apple's stock price drops by 1%
-
【ゆとりサイクルが始まった!歴史を鑑とする:FED金利調整と大統領選結果には“隠れた関連”があった】データによると、選挙日前に金利が引き上げられた5年間で、大統領やホワイトハウスを支配していた政党が4年連 ...
- 不正经的工程师
- 前天 21:56
- 支持
- 反对
- 回复
- 收藏
-
【トヨタが米国で約4万2000台のカローラCrossをリコール】トヨタ自動車は当時時間9月20日、2022年6月から2024年9月までに生産された一部のカローラCrossハイブリッド車を安全にリコールしていると発表した。リコー ...
- 伍六三
- 12 小时前
- 支持
- 反对
- 回复
- 收藏
-
アイルランドのライアン航空のオリーリ最高経営責任者は現地時間9月14日、最近のボーイング社員のストライキが、2025年夏までにライアン社に納入されるボーイング737 MAX機の数に影響を与える可能性があると述べた ...
- rlf2000
- 1 小时前
- 支持
- 反对
- 回复
- 收藏
-
インテルは9月19日、イスラエルの自動運転技術会社Mobileyeの大株主として、ビジネスの将来に自信を持っており、現在、同社の株式の多数を切り離す計画はないと発表した。 ...
- hecgdge4
- 前天 20:20
- 支持
- 反对
- 回复
- 收藏